SEC Filing Document

Company: BIOVENTRIX, INC.
Ticker: 
CIK: 1283259
Filing Type: S-1
Document Type: EX-10.8
Date Filed: 2026-02-12
Accession Number: 0001493152-26-006407
Exchange: 
SIC Code: 3841
SIC Description: Surgical & Medical Instruments & Apparatus
URL: https://www.sec.gov/Archives/edgar/data/1283259/000149315226006407/ex10-8.htm

Chunk 10 of 14
Word Count: 1477
Character Count: 9778

Document Content:

shall cause to be established, as soon as practicable after such request, and will maintain, an audit and compensation committee, each of which shall consist solely of non-management directors. Each non-employee director shall be entitled in such person’s discretion to be a member of any committee of the Board of Directors. 5.6 Successor Indemnification. If the Company or any of its successors or assignees consolidates with or merges into any other Person and is not the continuing or surviving corporation or entity of such consolidation or merger, then to the extent necessary, proper provision shall be made so that the successors and assignees of the Company assume the obligations of the Company with respect to indemnification of members of the Board of Directors as in effect immediately before such transaction, whether such obligations are contained in the Company’s Bylaws, the Certificate of Incorporation, or elsewhere, as the case may be.

5.7 Indemnification
Matters. The Company hereby acknowledges that one (1) or more of the Preferred Directors nominated to serve on the Board of Directors
by one (1) or more Investors may have certain rights to indemnification, advancement of expenses and/or insurance provided by one (1)
or more of the Investors and certain of their Affiliates (collectively, the “Investor Indemnitors”). The Company hereby
agrees (a) that it is the indemnitor of first resort (i.e., its obligations to any such Preferred Director are primary and any
obligation of the Investor Indemnitors to advance expenses or to provide indemnification for the same expenses or liabilities incurred
by such Preferred Director are secondary), (b) that it shall be required to advance the full amount of expenses incurred by such Preferred
Director and shall be liable for the full amount of all expenses, judgments, penalties, fines and amounts paid in settlement by or on
behalf of any such Preferred Director to the extent legally permitted and as required by the Certificate of Incorporation or Bylaws of
the Company (or any agreement between the Company and such Preferred Director), without regard to any rights such Preferred Director
may have against the Investor Indemnitors, and, (c) that it irrevocably waives, relinquishes and releases the Investor Indemnitors from
any and all claims against the Investor Indemnitors for contribution, subrogation or any other recovery of any kind in respect thereof.
The Company further agrees that no advancement or payment by the Investor Indemnitors on behalf of any such Preferred Director with respect
to any claim for which such Preferred Director has sought indemnification from the Company shall affect the foregoing and the Investor
Indemnitors shall have a right of contribution and/or be subrogated to the extent of such advancement or payment to all of the rights
of recovery of such Preferred Director against the Company. The Preferred Directors and the Investor Indemnitors are intended third-party
beneficiaries of this Section 5.7 and shall have the right, power and authority to enforce the provisions of this Section 5.7
as though they were a party to this Agreement.

5.1 Right
to Conduct Activities. The Company hereby agrees and acknowledges that BioDiscovery 6 FPCI (“Andera”) (together
with its Affiliates), Cormorant Private Healthcare Fund III, LP, Cormorant Private Healthcare Fund IV, LP, and Cormorant Global Healthcare
Master Fund, LP (“Cormorant”) (together with its Affiliates), and SQPE 2023 Fund LP (“Squarepoint”)
(together with its Affiliates) are professional investment organizations, and as such review the business plans and related proprietary
information of many enterprises, some of which may compete directly or indirectly with the Company’s business (as currently conducted
or as currently propose to be conducted). Nothing in this Agreement shall preclude or in any way restrict Andera, Cormorant, or Squarepoint
from evaluating or purchasing securities, including publicly traded securities, of a particular enterprise, or investing or participating
in any particular enterprise whether or not such enterprise has products or services which compete with those of the Company; and the
Company hereby agrees that, to the extent permitted under applicable law, Andera (and its Affiliates), Cormorant (and its Affiliates),
and Squarepoint (and its Affiliates) shall not be liable to the Company for any claim arising out of, or based upon, (i) the investment
by Andera (or its Affiliates), Cormorant (or its Affiliates), or Squarepoint (or its Affiliates) in any entity competitive with the Company,
or (ii) actions taken by any partner, officer, employee or other representative of Andera (or its Affiliates), Cormorant (or its Affiliates),
or Squarepoint (or its Affiliates) to assist any such competitive company, whether or not such action was taken as a member of the board
of directors of such competitive company or otherwise, and whether or not such action has a detrimental effect on the Company; provided,
however, that the foregoing shall not relieve (x) any of Andera, Cormorant, or Squarepoint from liability associated with the
unauthorized disclosure of the Company’s confidential information obtained pursuant to this Agreement, or (y) any director or officer
of the Company from any liability associated with his or her fiduciary duties to the Company.

5.2 Anti-Harassment
Policy. The Company shall, within sixty (60) days following the Closing (as defined in the Purchase Agreement), adopt and thereafter
maintain in effect (i) a Code of Conduct governing appropriate workplace behavior and (ii) an Anti-Harassment and Discrimination Policy
prohibiting discrimination and harassment at the Company. Such policy shall be reviewed and approved by the Board of Directors.

5.3 FCPA.
The Company covenants that it shall not (and shall not permit any of its subsidiaries or Affiliates or any of its or their respective
directors, officers, managers, employees, independent contractors, representatives or agents to) promise, authorize or make any payment
to, or otherwise contribute any item of value to, directly or indirectly, to any third party, including any Non-U.S. Official (as such
term is defined in the U.S. Foreign Corrupt Practices Act of 1977, as amended (the “FCPA”)), in each case, in violation
of the FCPA, the U.K. Bribery Act, or any other applicable anti-bribery or anti-corruption law. The Company further covenants that it
shall (and shall cause each of its subsidiaries and Affiliates to) cease all of its or their respective activities, as well as remediate
any actions taken by the Company, its subsidiaries or Affiliates, or any of their respective directors, officers, managers, employees,
independent contractors, representatives or agents in violation of the FCPA, the U.K. Bribery Act, or any other applicable anti-bribery
or anti-corruption law. The Company further covenants that it shall (and shall cause each of its subsidiaries and Affiliates to) maintain
systems of internal controls (including, but not limited to, accounting systems, purchasing systems and billing systems) to ensure compliance
with the FCPA, the U.K. Bribery Act, or any other applicable anti-bribery or anti-corruption law. Upon request, the Company agrees to
provide responsive information and/or certifications concerning its compliance with applicable anti-corruption laws. The Company shall
promptly notify each Investor if the Company becomes aware of any Enforcement Action (as defined in the Purchase Agreement). The Company
shall, and shall cause any direct or indirect subsidiary or entity controlled by it, whether now in existence or formed in the future,
to comply with the FCPA. The Company shall use its best efforts to cause any direct or indirect subsidiary, whether now in existence
or formed in the future, to comply in all material respects with all applicable laws.

5.4 Cybersecurity.
The Company shall, within one hundred eighty (180) days following the Closing (as defined in the Purchase Agreement), use
commercially reasonable efforts to (a) identify and restrict access (including through physical and/or technical controls) to the
Company’s confidential business information and trade secrets and any information about identified or identifiable natural
persons maintained by or on behalf of the Company (collectively, “Protected Data”) to those individuals who have
a need to access it and (b) implement reasonable physical, technical and administrative safeguards (“Cybersecurity
Solutions”) designed to protect the confidentiality, integrity and availability of its technology and systems (including
servers, laptops, desktops, cloud, containers, virtual environments and data centers) and all Protected Data. The Company shall use
commercially reasonable efforts to ensure that the Cybersecurity Solutions (x) are up-to-date and include industry-standard
protections (e.g., antivirus, endpoint detection and response and threat hunting), (y) to the extent determined necessary by
the Company or the Board of Directors, are backed by a breach prevention warranty from the vendor certifying the effectiveness of
such solutions, and (z) require the vendors to notify the Company of any security incidents posing a risk to the Company’s
information (regardless of whether information was actually compromised). The Company shall evaluate on a periodic basis at least
annually whether such safeguards should be updated to maintain a level of security appropriate to the risk posed to Company systems
and Protected Data. The Company shall educate its employees about the proper use and storage of Protected Data, including periodic
training as determined reasonably necessary by the Company or the Board of Directors.